The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.
 
Yuki Sato
Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Takeshi Masuda
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin International; Kyowa Kirin International; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - MSD K.K
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Motoko Tachihara
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst)
 
Shinobu Hosokawa
Speakers' Bureau - AstraZeneca Japan; Bristol Myers Squibb K.K.
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Taichi Miyawaki
No Relationships to Disclose
 
Kohei Yoshimine
No Relationships to Disclose
 
Masahide Mori
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Co Ltd; Kyowa Kirin; Lilly Japan; MSD K.K; Nippon Kayaku; Novartis Pharmaceuticals UK Ltd.; Ono Pharmaceutical; Otsuka; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Hideaki Shiraishi
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kosuke Hamai
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical
 
Koji Haratani
Honoraria - Bristol-Myers Squibb; MSD K.K; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; MSD K.K
 
Sumiko Maeda
No Relationships to Disclose
 
Eriko Tabata
No Relationships to Disclose
 
Chiyoe Kitagawa
Speakers' Bureau - Ono Yakuhin
Research Funding - Daiichi Sankyo/Astra Zeneca; Sanofi
 
Junko Tanizaki
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; EMD Serono/Merck; Lilly Japan; MSD; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Speakers' Bureau - AstraZeneca Japan
 
Takumi Imai
Honoraria - Kyowa Kirin
 
Nobuyuki Yamamoto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; GlaxoSmithKline; Hisamitsu Pharmaceutical; Janssen; Janssen; Kyowa Kirin International; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - Abbvie (Inst); Amgen (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bayer Yakuhin; CareNet; Chugai Pharma; CMIC; CMIC Co., Ltd.; Japan Clinical Research Operations; Kyowa Kirin Co., Ltd.; Kyowa Kirin Co., Ltd.; Life Technologies; Lilly Japan; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Neo Communication; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taiyo Pharma; Takeda; YODOSHA
Consulting or Advisory Role - Lilly Japan; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Janssen (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Mebix (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SRL Diagnostics (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo Co., Ltd. (Inst)
 
Noboru Hattori
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Kirin (Inst); Lilly Japan (Inst); MSD K.K (Inst); Taiho Pharmaceutical (Inst)